Sanofi and Lexicon Pharmaceuticals Inc. have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes. “This agreement with Lexicon reinforces our commitment to helping people living with diabetes,” said Pascale Witz, executive vice president, Sanofi, who w...